Tag Archives: Phenytoin

Phenobarbital: 15 mg; 30mg ; 60mg; 100mg. Uses and Administration

Phenobarbital is a barbiturate that may be used as an antiepileptic to control partial and generalised tonic-clonic seizures. It is also used as part of the emergency management of acute seizures including status epilepticus. The dose should be adjusted to the needs of the individual patient to achieve adequate control of seizures; this usually requires… Read More »

Lamotrigine: 25mg, 50mg, 100mg, 150mg, 200mg, 250mg. Uses and Administration

Lamotrigine, a phenyltriazine compound, is an antiepileptic used mainly for monotherapy or adjunctive treatment of partial seizures and primary and secondarily generalised tonic-clonic seizures. It may be used for seizures associated with the Lennox-Gastaut syndrome and for the maintenance treatment of bipolar disorder. The doses given below for the use of lamotrigine in epilepsy are… Read More »

Pharmacological Treatment of Pain

While medications are often prescribed for all types of chronic pain, research has consistently shown that several classes have proven efficacy for the treatment of neuropathic pain. Ideally, pharmacotherapy of pain would be specifically selected on the basis of considerations of etiology (e.g., ischemic, neuropathic), pathophysiology (e.g., demyelination, central pain), and anatomy (e.g., C fibers,… Read More »

Preventive Treatment for Migraine

Migraine is a common episodic headache disorder characterized by attacks that consist of various combinations of headache and neurologie, gastrointestinal, and autonomie symptoms. It has a one-year prevalence of approximately 18% in women, 6% in men, and 4% in children. The second edition of the International Classification of Headache Disorders (ICHD-2) subclassifies migraine into migraine… Read More »

Treatment Of Childhood Absence Epilepsy

Childhood absence epilepsy (CAE) typically requires treatment because the seizures are frequent and interfere with normal cognitive functioning. International League Against Epilepsy Guidelines (Newly Diagnosed Epilepsy) According to the ILAE guidelines, the absence of class I and class II randomized controlled trials (RCTs) for children with absence seizures implies a marked deficiency in adequately powered,… Read More »

Treatment Of Juvenile Myoclonic Epilepsy

ILAE Guidelines (Newly Diagnosed Epilepsy) Despite being a relatively common syndrome, there are no randomized trials reporting efficacy or effectiveness as a primary outcome measure in newly diagnosed juvenile myoclonic epilepsy. Valproate has long been regarded as the drug of choice to treat this condition. ‘In the absence of class I, class II and class… Read More »

Treatment Of IGE With GTC Seizures Only

The syndrome of primary generalized-onset tonic–clonic seizures presents the clinician with nosologic, diagnostic and treatment difficulties. Some patients with IGE appear to have generalized-onset tonic–clonic seizures alone and the 1989 ILAE epilepsy classification individualized epilepsy with grand mal seizures on awakening and epilepsies with specific modes of precipitation. The evolving classification of IGE uses more… Read More »

Treatment Of Childhood Absence Epilepsy: American Academy Of Neurology Guidelines

New Anti-Epileptic Drugs Only American Academy of Neurology (AAN) guidelines evaluating efficacy of new anti-epileptic drugs state only that lamotrigine is effective in children with newly diagnosed absence seizures (level B recommendation). Ethosuximide After ethosuximide was described as effective in absence epilepsy in 1958, a number of open-label, non-comparative studies where ethosuximide was added to… Read More »

Treatment Of The Child Or Adolescent With Newly Diagnosed Epilepsy

Paediatric epilepsy is amazingly diverse. In some children, basic diagnosis, seizure classification and treatment are straightforward. Other patients have difficult-to-diagnose seizures, complicated seizure classification and a variable response to treatment. Some seizures are subclinical, others are barely noticeable, and occasionally they are life threatening. Many children with epilepsy have no associated disabilities, but all children… Read More »

Mitoxantrone in Multiple Sclerosis

Mitoxantrone () was developed in the 1970s and is an antineoplastic agent. It is an anthracenedione derivative related to the anthracyclins doxorubicine and daunorubicine. It interacts with topoisomerase-2, stabilizes its cleavable complex with DNA, thus prevents the ligation of DNA strands, and consecutively delays the cell-cycle progression. Mitoxantrone is used to effectively treat malignancies such… Read More »